Lexaria Bioscience (LEXX) has released an update.
Lexaria Bioscience Corp. announces the appointment of Richard Christopher as the new CEO, with outgoing CEO Chris Bunka transitioning to Chairman and Executive Strategic Advisor. Christopher brings over three decades of experience to Lexaria, aiming to navigate the company through a period of growth, particularly in the GLP-1 drug delivery market. Bunka expresses his confidence in Christopher’s leadership as the company focuses on pharmaceutical collaborations and operations.
For further insights into LEXX stock, check out TipRanks’ Stock Analysis page.
